Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Lantheus stock
Learn how to easily invest in Lantheus stock.
Lantheus Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Lantheus shares (LNTH) are listed on the NASDAQ and all prices are listed in US Dollars. Lantheus employs 612 staff and has a trailing 12-month revenue of around $664.2 million.
How to buy shares in Lantheus
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – LNTH – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Lantheus stock price (NASDAQ: LNTH)Use our graph to track the performance of LNTH stocks over time.
Lantheus shares at a glance
|Latest market close||$68.36|
|52-week range||$22.20 - $87.47|
|50-day moving average||$78.33|
|200-day moving average||$56.10|
|Wall St. target price||$103.20|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.39|
Buy Lantheus shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Lantheus stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Lantheus price performance over time
|1 week (2022-09-19)||-11.45%|
|1 month (2022-08-26)||-16.13%|
|3 months (2022-06-24)||8.82%|
|6 months (2022-03-23)||23.17%|
|1 year (2021-09-24)||153.47%|
|2 years (2020-09-25)||460.33%|
|3 years (2019-09-26)||162.02%|
|5 years (2017-09-26)||291.75%|
Is Lantheus stock undervalued or overvalued?
Valuing Lantheus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lantheus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lantheus's P/E ratio
Lantheus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 175x. In other words, Lantheus shares trade at around 175x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Lantheus's PEG ratio
Lantheus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lantheus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Lantheus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $200.8 million.
The EBITDA is a measure of a Lantheus's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$664.2 million|
|Operating margin TTM||22.94%|
|Gross profit TTM||$187.7 million|
|Return on assets TTM||10.18%|
|Return on equity TTM||6.02%|
|Market capitalisation||$4.7 billion|
TTM: trailing 12 months
Lantheus share dividends
We're not expecting Lantheus to pay a dividend over the next 12 months.
Lantheus share price volatility
Over the last 12 months, Lantheus's shares have ranged in value from as little as $22.2 up to $87.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantheus's is 0.7727. This would suggest that Lantheus's shares are less volatile than average (for this exchange).
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.
Lantheus in the news
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
A 'Game-Changing' Tool In Prostate Cancer Stokes A Huge Gain For Lantheus Stock
3 Top Ranked Stocks for Exposure to the Medical Sector
Frequently asked questionsWhat percentage of Lantheus is owned by insiders or institutions?
Currently 2.445% of Lantheus shares are held by insiders and 101.293% by institutions. How many people work for Lantheus?
Latest data suggests 612 work at Lantheus. When does the fiscal year end for Lantheus?
Lantheus's fiscal year ends in December. Where is Lantheus based?
Lantheus's address is: 331 Treble Cove Road, North Billerica, MA, United States, 01862 What is Lantheus's ISIN number?
Lantheus's international securities identification number is: US5165441032 What is Lantheus's CUSIP number?
Lantheus's Committee on Uniform Securities Identification Procedures number is: 516544103
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert